Application No. 09/724,288 Amendment dated December 20, 2007 Reply to Office Action of October 3, 2007

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1-91. (Canceled)

92. (Currently Amended) A method of claim 90, screening an antibody for activity in inducing clearance of an amyloid deposit of AB, comprising:

combining the amyloid deposit, the antibody, and microglial cells bearing Fc receptors in a medium in vitro, wherein the combining comprises combining the amyloid deposit and the antibody before adding the microglial cells bearing Fc receptors; and

by a series of measurements, monitoring whether a reduction in the amount of the amyloid deposit remaining in the medium occurs, as compared to a baseline measurement, a reduction in the amount of the amyloid deposit indicating the antibody induces phagocytic clearing activity of the microglial cells against the amyloid deposit.

93-96. (Canceled)

97. (Currently Amended) The method of <u>screening a monoclonal antibody for</u> activity in inducing clearance of an amyloid deposit of Aβ, comprising:

combining the amyloid deposit, elaim 90, wherein the antibody is a monoclonal antibody, and microglial cells bearing Fc receptors in a medium in vitro; and

by a series of measurements, monitoring whether a reduction in the amount of the amyloid deposit remaining in the medium occurs, as compared to a baseline measurement, a reduction in the amount of the amyloid deposit indicating the monoclonal antibody induces phagocytic clearing activity of the microglial cells against the amyloid-deposit.

Application No. 09/724,288 Amendment dated December 20, 2007 Reply to Office Action of October 3, 2007

 (Currently Amended) The method of elaim 97,screening a monoclonal antibody for activity in inducing clearance of an amyloid deposit of Aβ, comprising:

combining the amyloid deposit, a wherein the monoclonal antibody which binds to an epitope within amino acid residues 1-7 of $A\beta$, and microglial cells bearing Fc receptors in a medium in vitro; and

by a series of measurements, monitoring whether a reduction in the amount of the amyloid deposit remaining in the medium occurs, as compared to a baseline measurement, a reduction in the amount of the amyloid deposit indicating the monoclonal antibody induces phagocytic clearing activity of the microglial cells against the amyloid deposit.

99. (Canceled)

. 100. (Currently Amended) The method of elaim 97, screening a monoclonal antibody for activity in inducing clearance of an amyloid deposit of Aβ, comprising:

combining the amyloid deposit, a monoclonal antibody, and microglial cells
bearing Fc receptors in a medium in vitro, wherein the amyloid deposit is a tissue sample from
the brain of an Alzheimer's disease patient or an animal having Alzheimer's pathology, and

by a series of measurements, monitoring whether a reduction in the amount of the amyloid deposit remaining in the medium occurs, as compared to a baseline measurement, a reduction in the amount of the amyloid deposit indicating the monoclonal antibody induces phagocytic clearing activity of the microglial cells against the amyloid-deposit.